Nuvectis Pharma (NVCT) Interest & Investment Income (2022 - 2026)

Nuvectis Pharma has reported Interest & Investment Income for 5 years, with the latest figure at $210000.0 in Q1 2026.

• Quarterly Interest & Investment Income fell 11.02% year-over-year to $210000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 28.9% YoY) and the FY2025 annual result came in at $1.1 million, up 33.65% from the prior year.
• Interest & Investment Income slipped to $210000.0 in Q1 2026 per NVCT's latest filing, from $303000.0 in the prior quarter.
• Over five years, Interest & Investment Income peaked at $332000.0 in Q3 2025 and troughed at $2000.0 in Q1 2022.
• A 5-year average of $175000.0 and a median of $210000.0 in 2026 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2023 and 2024: Interest & Investment Income soared 2500.0% in 2023, then fell 25.63% in 2024.
• Over 5 years, Interest & Investment Income stood at $82000.0 in 2022, then surged by 197.56% to $244000.0 in 2023, then dropped by 17.62% to $201000.0 in 2024, then jumped by 50.75% to $303000.0 in 2025, then plunged by 30.69% to $210000.0 in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $210000.0, $303000.0, and $332000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.